Correlation Between Adaptimmune Therapeutics and ADC Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Adaptimmune Therapeutics and ADC Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Adaptimmune Therapeutics and ADC Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Adaptimmune Therapeutics Plc and ADC Therapeutics SA, you can compare the effects of market volatilities on Adaptimmune Therapeutics and ADC Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Adaptimmune Therapeutics with a short position of ADC Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Adaptimmune Therapeutics and ADC Therapeutics.

Diversification Opportunities for Adaptimmune Therapeutics and ADC Therapeutics

0.45
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Adaptimmune and ADC is 0.45. Overlapping area represents the amount of risk that can be diversified away by holding Adaptimmune Therapeutics Plc and ADC Therapeutics SA in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on ADC Therapeutics and Adaptimmune Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Adaptimmune Therapeutics Plc are associated (or correlated) with ADC Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of ADC Therapeutics has no effect on the direction of Adaptimmune Therapeutics i.e., Adaptimmune Therapeutics and ADC Therapeutics go up and down completely randomly.

Pair Corralation between Adaptimmune Therapeutics and ADC Therapeutics

Given the investment horizon of 90 days Adaptimmune Therapeutics Plc is expected to under-perform the ADC Therapeutics. In addition to that, Adaptimmune Therapeutics is 1.05 times more volatile than ADC Therapeutics SA. It trades about -0.15 of its total potential returns per unit of risk. ADC Therapeutics SA is currently generating about -0.05 per unit of volatility. If you would invest  273.00  in ADC Therapeutics SA on August 31, 2024 and sell it today you would lose (47.00) from holding ADC Therapeutics SA or give up 17.22% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Adaptimmune Therapeutics Plc  vs.  ADC Therapeutics SA

 Performance 
       Timeline  
Adaptimmune Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Adaptimmune Therapeutics Plc has generated negative risk-adjusted returns adding no value to investors with long positions. Even with conflicting performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in December 2024. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.
ADC Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days ADC Therapeutics SA has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fragile performance in the last few months, the Stock's fundamental indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Adaptimmune Therapeutics and ADC Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Adaptimmune Therapeutics and ADC Therapeutics

The main advantage of trading using opposite Adaptimmune Therapeutics and ADC Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Adaptimmune Therapeutics position performs unexpectedly, ADC Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ADC Therapeutics will offset losses from the drop in ADC Therapeutics' long position.
The idea behind Adaptimmune Therapeutics Plc and ADC Therapeutics SA pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Other Complementary Tools

Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments